Pediatric Vaccine Market to Reach $62.50 Billion by 2035

Pediatric vaccine market was valued at $31.80 billion in 2025 and is projected to reach $62.50 billion by 2035, growing at a CAGR of 6.3% during the forecast period (2026–2035). The increasing expansion of national immunization programs and rising awareness of preventive healthcare are significantly driving demand for pediatric vaccines across global healthcare systems. Governments and global health agencies are prioritizing childhood immunization to reduce disease burden and mortality, thereby strengthening long-term demand for vaccines. The rising global immunization coverage is a major macro driver supporting market growth. According to the World Health Organization (WHO), routine immunization programs currently reach over 110 million infants annually, with global DTP3 vaccine coverage estimated at approximately 84%. WHO also states that immunization prevents between 3.5 million and 5 million deaths each year from vaccine-preventable diseases such as measles, tetanus, and diphtheria. This strong statistical evidence highlights the critical role of pediatric vaccines in public health and directly supports increased investment and production across global markets.

Browse the full report description of “Pediatric Vaccine Market Size, Share & Trends Analysis Report, By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit & Conjugate Vaccines, mRNA Vaccines, Viral Vector Vaccines), By Vaccine Composition (Monovalent, Multivalent), By Technology Platform (Traditional, Next-Generation), By End-User (Hospitals, Pediatric Clinics, Community Health Centers), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/pediatric-vaccine-market

The growing demand for combination vaccines and next-generation vaccine platforms is further transforming the pediatric vaccine landscape. Multivalent vaccines are increasingly preferred due to their ability to protect against multiple diseases in a single dose, improving compliance and reducing healthcare burden. In addition, advancements in mRNA and viral vector technologies are enabling faster vaccine development and improved efficacy, accelerating product innovation and market penetration. From an end-user perspective, hospitals and pediatric clinics remain the dominant channels for vaccine administration, supported by government immunisation schedules and healthcare infrastructure. Meanwhile, community health centres and vaccination camps are playing a critical role in improving access in rural and underserved regions, particularly across the Asia-Pacific and Africa. Expanding healthcare infrastructure and government-funded vaccination drives are reinforcing consistent vaccine uptake across these regions.

Key market players are actively implementing strategic initiatives such as product innovation, capacity expansion, and partnerships to strengthen their global presence:

• In March 2026, GSK plc. has received approval from China’s National Medical Products Administration (NMPA) for Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 years and above.
• In February 2026, received full FDA approval for BRAFTOVI (encorafenib) in combination therapy for treating metastatic colorectal cancer with a BRAF V600E mutation. The therapy showed significant improvements in progression-free survival, overall survival, and response rates compared to standard treatment.

These strategies are enhancing supply capabilities, improving accessibility, and supporting long-term market growth. The pediatric vaccine market continues to benefit from strong regulatory support, public-private partnerships, and sustained investments in vaccine innovation, reinforcing its critical role in global healthcare systems.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Vaccine Type
  • Vaccine Composition
  • Technology Platform
  • End-Users
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – GSK plc., Merck & Co., Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Pediatric Vaccine Market Report Segment

By Vaccine Type

• Live Attenuated Vaccines
• Inactivated (Killed) Vaccines
• Subunit, Recombinant, Polysaccharide & Conjugate Vaccines
• mRNA Vaccines
• Viral Vector-Based Vaccines

By Vaccine Composition

• Monovalent Vaccines
• Multivalent / Combination Vaccines

By Technology Platform

• Traditional Vaccine Platforms
• Next-Generation Platforms

By End-User

• Hospitals
• Pediatric Clinics
• Community Health Centers / Vaccination Camps

Global Pediatric Vaccine Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/pediatric-vaccine-market